Also, several works reported that the lowest reproducibility of Ki67 results is mainly observed in the subset of cancers with intermediate proliferation activity (between 15 and 30%), the range in which most cutoffs are located for making clinical decisions [23–25], this further impede the clinical utility of Kin67 and make it difficult to compare Ki67 data across different studies. The gene discussed is MKI67; the disease is cancer.